申请人:Betta Pharmaceuticals Co., Ltd
公开号:EP4105207A1
公开(公告)日:2022-12-21
The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.
本发明涉及一种式(I)的化合物,以及使用该化合物作为EGFR抑制剂的方法和包含该化合物的药物组合物。该化合物可用于治疗、预防或缓解癌症或感染等疾病或障碍。